FOXP1 regulation via the PI3K/Akt/p70S6K signaling pathway in breast cancer cells

Halacli,Sevil  Oskay; Dogan,Ayse  Lale

doi:10.3892/ol.2015.2885

FOXP1 regulation via the PI3K/Akt/p70S6K signaling pathway in breast cancer cells

Authors:
- Sevil Oskay Halacli
- Ayse Lale Dogan
View Affiliations

Affiliations: Pediatric Immunology Unit, Institute of Children's Health, Hacettepe University, Ankara 06100, Turkey, Department of Basic Oncology, Institute of Oncology, Hacettepe University, Ankara 06100, Turkey
Published online on: January 16, 2015 https://doi.org/10.3892/ol.2015.2885
Pages: 1482-1488

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Loss of Forkhead box P1 (FOXP1) protein expression confers a poor prognosis in sporadic and familial breast cancer patients, and the FOXP1 gene maps to a tumor suppressor locus at chromosome 3p14. Although correlation studies have indicated that FOXP1 has a role in tumor suppression, determination of the regulatory mechanism of FOXP1 is required to establish its function in breast cancer. It has previously been identified that FOXP1 is regulated by estrogen in breast cancer and that treatment with bisphenol A is effective for regulating the transformation of the normal human breast epithelial cell line, MCF‑10F. In addition, FOXO‑regulated activation of FOXP1 inhibits the apoptosis of MCF‑10F cells following tamoxifen and Akt inhibitor VIII administration. The present study indicates that FOXP1 regulation occurs via a PI3K/Akt/p70S6 kinase (p70S6K) signaling pathway. Following treatment with wortmannin, an inhibitor of phosphatidylinositol 3‑kinase (PI3K)/Akt, MCF7 and MDA‑MB‑231 breast cancer cells demonstrated decreased FOXP1 protein expression levels; this result was also observed in the small interfering (si)RNA silencing of Akt. By contrast, overexpression of Akt resulted in increased FOXP1 protein expression levels in the MDA‑MB‑231 cells compared with the control cell lysates. Furthermore, treatment with rapamycin, a specific inhibitor of the mammalian target of rapamycin/p70S6K cascade, resulted in decreased FOXP1 expression in the MCF7 cells, but not in the MDA‑MB‑231 cells, which were resistant to rapamycin‑induced inhibition. In addition, silencing of p70S6K using siRNA produced a marked decrease in FOXP1 expression. These data indicate that FOXP1 protein expression is regulated by a PI3K/Akt/p70S6K signaling cascade in breast cancer.

View Figures

View References

1	Beelen K, Hoefnagel LD, Opdam M, et al: PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy. Int J Cancer. 135:1257–1263. 2014. View Article : Google Scholar : PubMed/NCBI
2	Zhang Y, Tseng CC, Tsai YL, et al: Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI(3,4,5)P3 production. PLoS One. 8:e800712013. View Article : Google Scholar : PubMed/NCBI
3	Chin YR and Toker A: Akt isoform-specific signaling in breast cancer: uncovering an anti-migratory role for palladin. Cell Adh Migr. 5:211–214. 2011. View Article : Google Scholar : PubMed/NCBI
4	Shin S, Wolgamott L, Yu Y, et al: Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci USA. 108:E1204–E1213. 2011. View Article : Google Scholar : PubMed/NCBI
5	Matassa DS, Agliarulo I, Amoroso MR, et al: TRAP1-dependent regulation of p70S6K is involved in the attenuation of protein synthesis and cell migration: Relevance in human colorectal tumors. Mol Oncol. 8:1482–1494. 2014. View Article : Google Scholar : PubMed/NCBI
6	Segatto I, Berton S, Sonego M, et al: p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation. Mol Oncol. 8:766–780. 2014. View Article : Google Scholar : PubMed/NCBI
7	Plas DR and Thompson CB: Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J Biol Chem. 278:12361–12366. 2003. View Article : Google Scholar : PubMed/NCBI
8	Brunet A, Bonni A, Zigmond MJ, et al: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
9	Biggs WH III, Meisenhelder J, Hunter T, et al: Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA. 96:7421–7426. 1999. View Article : Google Scholar : PubMed/NCBI
10	van Boxtel R, Gomez-Puerto C, Mokry M, et al: FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis. Cell Death Differ. 20:1219–1229. 2013. View Article : Google Scholar : PubMed/NCBI
11	Banham AH, Beasley N, Campo E, et al: The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res. 61:8820–8829. 2001.PubMed/NCBI
12	Brown PJ, Ashe SL, Leich E, et al: Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood. 111:2816–2824. 2008. View Article : Google Scholar
13	Bates GJ, Fox SB, Han C, et al: Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. Breast Cancer Res Treat. 111:453–459. 2008. View Article : Google Scholar
14	Shigekawa T, Ijichi N, Ikeda K, et al: FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Horm Cancer. 2:286–297. 2011. View Article : Google Scholar : PubMed/NCBI
15	Banham AH, Boddy J, Launchbury R, et al: Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. Prostate. 67:1091–1098. 2007. View Article : Google Scholar : PubMed/NCBI
16	Rayoo M, Yan M, Takano EA, et al: Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers. J Clin Pathol. 62:896–902. 2009. View Article : Google Scholar : PubMed/NCBI
17	McMahon LP, Yue W, Santen RJ and Lawrence JC Jr: Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. Mol Endocrinol. 19:175–183. 2005. View Article : Google Scholar
18	Tiwary R, Yu W, Sanders BG and Kline K: α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways. Br J Cancer. 104:101–109. 2011. View Article : Google Scholar :
19	Carracedo A, Ma L, Teruya-Feldstein J, et al: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 118:3065–3074. 2008.PubMed/NCBI
20	Sangai T, Akcakanat A, Chen H, et al: Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 18:5816–5828. 2012. View Article : Google Scholar : PubMed/NCBI
21	Noh WC, Mondesire WH, Peng J, et al: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res. 10:1013–1023. 2004. View Article : Google Scholar : PubMed/NCBI
22	Yellen P, Saqcena M, Salloum D, et al: High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle. 10:3948–3956. 2011. View Article : Google Scholar : PubMed/NCBI
23	Chen Y, Zheng Y and Foster DA: Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene. 22:3937–3942. 2003. View Article : Google Scholar : PubMed/NCBI
24	Meric-Bernstam F, Akcakanat A, Chen H, et al: PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 18:1777–1789. 2012. View Article : Google Scholar : PubMed/NCBI
25	O’Reilly KE, Rojo F, She QB, et al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500–1508. 2006. View Article : Google Scholar
26	Breuleux M, Klopfenstein M, Stephan C, et al: Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther. 8:742–753. 2009. View Article : Google Scholar : PubMed/NCBI
27	Holz MK and Blenis J: Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem. 280:26089–26093. 2005. View Article : Google Scholar : PubMed/NCBI
28	Holz MK, Ballif BA, Gygi SP and Blenis J: mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 123:569–580. 2005. View Article : Google Scholar : PubMed/NCBI
29	Gomez GG, Volinia S, Croce CM, et al: Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Res. 74:1429–1439. 2014. View Article : Google Scholar : PubMed/NCBI
30	Qin J, Xu Y, Li X, et al: Effects of lentiviral-mediated Foxp1 and Foxq1 RNAi on the hepatocarcinoma cell. Exp Mol Pathol. 96:1–8. 2014. View Article : Google Scholar
31	Feng J, Zhang X, Zhu H, et al: High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol. 138:230–235. 2012. View Article : Google Scholar : PubMed/NCBI
32	Krohn A, Seidel A, Burkhardt L, et al: Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers. J Pathol. 231:130–141. 2013. View Article : Google Scholar : PubMed/NCBI